|
Every supplement seller has the right to a product that:
-
is patented
-
has filed for drug approval
-
has its first EPA approval
-
has numerous universities and other independent laboratories backing its product with tests and information
-
has head-to-head comparisons against prescription antibiotics
-
has safety data
-
has successfully performed tests against bacteria, yeasts and viruses
-
has been tested for use in water treatment
This product is now available…there is only one NanoSil…don’t be fooled by imitators!
Introduction
ConSeal presents this product that is non-toxic and yet lethal to bacteria, yeasts and some viruses. The product has been tested in thousands of tests against some of the deadliest bacteria that exist on the planet, and has been proven to easily kill every single bacteria tested so far. Numerous tests at major US universities and commercial labs like: UC Davis, Kansas State, Brigham Young University, UT, and many other independent laboratories and universities, have proven the effectiveness of the product in killing thousands of strains of problematic bacteria like; Staph, TB, Strep, E-coli, Salmonella, a number of yeasts, and even the anthrax spore, etc. We believe that the NanoSil® product is the only non-toxic product that has been proven to kill the anthrax spore.
ConSeal' Product Executive Summary
Patented
ConSeal is the only producer of a antibacterial product of this type that has been approved for patent by the United States Patent Agency since approximately 1924. The first patent was issued on 4/10/01 with an additional patent issued in 2004. We have other patents pending including a use patent. ConSeal is now the only manufacturer in the world with a patent on this type of antibacterial product. The patents have been filed for protection in 95 countries including Japan. FDA NanoSil® has been filed with the US FDA for drug approval in both humans and animals. The company has received approval by the FDA to begin testing of the product.
Foreign Drug Approvals
After conducting its own testing on NanoSil®, the Food and Drug Board of Ghana, West Africa, has approved ConSeal's NanoSil® product as a drug in the homeopathic category.
EPA Approval Disinfectant
NanoSil® has been approved by the United States EPA as a broad spectrum surface disinfectant,able to be used in hospitals, medical environments, residential homes, commercial buildings, as well asbusinesses. It has been approved for use against the most deadly bacterial pathogens in the United States including: Gram positive bacteria like Staphylococcus aureus (the most deadly bacteria in U.S. hospitals), Gram negative bacteria like Salmonella choleraesuis (food poisoning), and also Nosocomial or hospital induced pathogens like Pseudomonas aeruginosa (burns and cuts). Although this product is extremely deadly to bacteria, it has a unique competitive advantage. It has no smell, no color and is completely non-toxic (it uses no chemicals). It can be sprayed in and around areas where critical patients are or wherepeople live and work without endangering there lives with toxic chemicals. The product is so safe that if a child were to accidentally drink a whole bottle, he or she would not be harmed in any way. The new EPA approval states that the product can be used on hard surfaces including walls, tables, chairs, light fixtures, bathrooms, surfaces made of glass, porcelain, metal, glazed ceramic, and enameled and painted surfaces.
Safety/Toxicity
ConSeal hired an international and independent laboratory to do a toxicology study on NanoSil®. The test, called an LD-50 test, was performed in accordance with the guidelines of the Federal Hazardous Substances Act (FHSA) Regulations, 16 CFR 1500. In the test work, the NanoSil® was given to a number of both male and female test animals. The amount of NanoSil® given to the animals was 5g/kg of 22 ppm solution, or the equivalent of a 200 pound man taking 192 teaspoons or about 4 full 8 ounce bottles of the 10 ppm solution at one time (the normal adult dosage is one or two teaspoons/day). As a result of the test work, the independent laboratory made the following conclusion, "Under the conditions of this study, there was no mortality or significant evidence of toxicity observed in the rats. The test article (NanoSil®) would not be considered toxic at a dose of 5g/kg by oral route in the rat."
Testing
Numerous independent hospitals, universities and private laboratories have been, and currently are, doing test work on the NanoSil® as an antibiotic alternative and as a safe, external bacteria killing agent. Human tests for both external and internal usage are currently underway. Test work completed to date includes: antibiotic test comparisons; thousands of tests against different kinds of bacteria; yeast elimination work; safety and toxicity data; independent tests against other, similar silver products; water treatment tests, surface disinfectant tests, etc.
New Testing
ConSeal is constantly striving to gain new and important information on the effectiveness and uses of its product. ConSeal currently has several new studies and a double-blind clinical trial underway, with several more studies already in the planning stages. The new studies include a major 2.5 year (peer-reviewed) alternative to antibiotics study, direct human clinical tests at a number of hospitals in West Africa, along with a series of both bacteria and sporicidal tests on Anthrax and SARS. Studies have also been conducted by VIRIDIS BioPharma Laboratories in India verifying the "Viricidal Activity of NanoSil® against Hepatitis B Virus & the Cytotoxicity of NanoSil® along with the "Selective Inaction of NanoSil® on Probiotics".
|